Finnish Medical Technology Companies Revenio and Optomed Report Mixed Half-Year Results for 2024

Revenio Group Corporation's Performance

Revenio Group Corporation, a health technology company focusing on ophthalmic diagnostic solutions, reported a mixed performance for the first half of 2024. The company's net sales decreased by 9.0% to EUR 40.8 million, compared to EUR 44.8 million in the same period last year 1

1

. This decline was primarily attributed to the challenging market conditions, particularly in the United States.

Despite the decrease in net sales, Revenio managed to maintain a strong EBITDA margin of 31.1%, although this was down from 35.0% in the previous year. The company's operating profit (EBIT) also saw a decline, dropping to EUR 10.7 million from EUR 13.5 million in the first half of 2023 1

1

.

Optomed's Financial Results

In contrast, Optomed Plc, a company specializing in handheld fundus cameras and AI-based screening software, reported a significant improvement in its financial performance for the same period. The company's net sales grew by 29.8% to EUR 9.5 million, up from EUR 7.3 million in the first half of 2023 2

2

.

Optomed's gross margin also saw an improvement, increasing to 72.5% from 71.0% in the previous year. The company's EBITDA turned positive at EUR 0.3 million, compared to a loss of EUR 1.9 million in the same period of 2023. Operating result (EBIT) also improved significantly, with a loss of EUR 1.0 million, compared to a loss of EUR 3.1 million in the first half of 2023 2

2

.

Market Challenges and Strategic Responses

Both companies faced challenges in the global market, particularly due to economic uncertainties and changes in customer behavior. Revenio reported that the US market, in particular, showed signs of customers postponing their investment decisions 1

1

. To address these challenges, Revenio has implemented cost-saving measures and is focusing on maintaining its strong market position.

Optomed, on the other hand, has seen success with its strategic focus on the Devices segment and the US market. The company reported that its US sales more than doubled compared to the previous year, indicating a strong market reception for its products in that region 2

2

.

Future Outlook

Looking ahead, both companies remain cautiously optimistic. Revenio maintains its previous outlook for 2024, expecting net sales to remain at the same level as in 2023, with profitability (EBITDA) expected to remain at a good level 1

1

. Optomed has raised its financial guidance for 2024, now expecting full-year 2024 net sales to grow by 20-30% compared to 2023, driven by the strong performance in the first half of the year 2

2

.

These contrasting results highlight the diverse challenges and opportunities in the medical technology sector, with companies adapting their strategies to navigate the complex global market landscape.